spironolactone has been researched along with Fatty Liver in 8 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because the renin-angiotensin-aldosterone system has been implicated in the development of insulin resistance and promotion of fibrosis in some tissues, such as the vasculature, we examined the effect of eplerenone, a selective mineralocorticoid receptor (MR) antagonist, on nonalcoholic steatohepatitis (NASH) and metabolic phenotypes in a mouse model reflecting metabolic syndrome in humans." | 7.79 | Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. ( Aruga, Y; Ishii, Y; Kanasaki, K; Kitada, M; Koya, D; Miyashita, Y; Nakamura, Y; Sasahara, M; Sasaki, M; Sasaoka, T; Shimano, H; Tsuneki, H; Wada, T, 2013) |
| "Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease." | 7.76 | Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. ( Kenmochi, H; Koya, D; Miyashita, Y; Ojima, M; Sasahara, M; Sasaki, M; Sasaoka, T; Tsuneki, H; Wada, T, 2010) |
| "Because the renin-angiotensin-aldosterone system has been implicated in the development of insulin resistance and promotion of fibrosis in some tissues, such as the vasculature, we examined the effect of eplerenone, a selective mineralocorticoid receptor (MR) antagonist, on nonalcoholic steatohepatitis (NASH) and metabolic phenotypes in a mouse model reflecting metabolic syndrome in humans." | 3.79 | Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. ( Aruga, Y; Ishii, Y; Kanasaki, K; Kitada, M; Koya, D; Miyashita, Y; Nakamura, Y; Sasahara, M; Sasaki, M; Sasaoka, T; Shimano, H; Tsuneki, H; Wada, T, 2013) |
| "Recent evidence suggests that treatment with mineralocorticoid receptor antagonist suppressed local inflammation in vascular tissues or cardiomyocytes; therefore, we examined the effect of spironolactone on glucose and lipid metabolism in a mouse model with diet-induced diabetes and nonalcoholic fatty liver disease." | 3.76 | Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. ( Kenmochi, H; Koya, D; Miyashita, Y; Ojima, M; Sasahara, M; Sasaki, M; Sasaoka, T; Tsuneki, H; Wada, T, 2010) |
| " We determined the effects of SR alone or in combination with the antioxidant α-glycosyl isoquercitrin (AGIQ) on hyperlipidemia- and steatosis-related precancerous lesions in high-fat diet (HFD)-fed rats subjected to a two-stage hepatocarcinogenesis model." | 1.48 | Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation. ( Eguchi, A; Hayashi, SM; Kawashima, M; Kimura, M; Koyanagi, M; Makino, E; Maronpot, RR; Mizukami, S; Murayama, H; Nagahara, R; Nakamura, M; Ohtsuka, R; Shibutani, M; Takahashi, N; Yoshida, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Habibi, J | 1 |
| Chen, D | 1 |
| Hulse, JL | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Jia, G | 1 |
| de Zegher, F | 1 |
| Díaz, M | 1 |
| Villarroya, J | 1 |
| Cairó, M | 1 |
| López-Bermejo, A | 1 |
| Villarroya, F | 1 |
| Ibáñez, L | 1 |
| Murayama, H | 1 |
| Eguchi, A | 1 |
| Nakamura, M | 1 |
| Kawashima, M | 1 |
| Nagahara, R | 1 |
| Mizukami, S | 1 |
| Kimura, M | 1 |
| Makino, E | 1 |
| Takahashi, N | 1 |
| Ohtsuka, R | 1 |
| Koyanagi, M | 1 |
| Hayashi, SM | 1 |
| Maronpot, RR | 1 |
| Shibutani, M | 1 |
| Yoshida, T | 1 |
| Gamliel-Lazarovich, A | 1 |
| Raz-Pasteur, A | 1 |
| Coleman, R | 1 |
| Keidar, S | 1 |
| Wada, T | 2 |
| Miyashita, Y | 2 |
| Sasaki, M | 2 |
| Aruga, Y | 1 |
| Nakamura, Y | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 2 |
| Kanasaki, K | 1 |
| Kitada, M | 1 |
| Koya, D | 2 |
| Shimano, H | 1 |
| Tsuneki, H | 2 |
| Sasaoka, T | 2 |
| Kenmochi, H | 1 |
| Ojima, M | 1 |
| Polyzos, SA | 1 |
| Kountouras, J | 1 |
| Zafeiriadou, E | 1 |
| Patsiaoura, K | 1 |
| Katsiki, E | 1 |
| Deretzi, G | 1 |
| Zavos, C | 1 |
| Tsarouchas, G | 1 |
| Rakitzi, P | 1 |
| Slavakis, A | 1 |
| Salas, M | 1 |
| Tuchweber, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
| The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study[NCT01147523] | Phase 2 | 30 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for spironolactone and Fatty Liver
| Article | Year |
|---|---|
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 1 | 2021 |
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Female; Humans; Insulin Resistance; Male; Mice; Middle Aged; Mineralocorticoid | 2011 |
6 other studies available for spironolactone and Fatty Liver
| Article | Year |
|---|---|
Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance.
Topics: Animals; Diet, High-Fat; Diet, Western; Fatty Liver; Insulin; Insulin Resistance; Liver; Mice; Mice, | 2022 |
Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation.
Topics: Animals; Body Weight; Diet, High-Fat; Drug Therapy, Combination; Fatty Liver; Liver Neoplasms, Exper | 2018 |
The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
Topics: Adrenalectomy; Aldosterone; Animals; Blood Glucose; Blood Pressure; Cells, Cultured; Cholesterol; Di | 2013 |
Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet.
Topics: Animals; Cells, Cultured; Diet, High-Fat; Dietary Carbohydrates; Eplerenone; Fatty Liver; Fructose; | 2013 |
Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.
Topics: Animals; Body Weight; Cells, Cultured; Dietary Carbohydrates; Dietary Fats; Fatty Liver; Gene Expres | 2010 |
Prevention by steroids of cerium hepatotoxicity.
Topics: Animals; Cerium; Chemical and Drug Induced Liver Injury; Dexamethasone; Endoplasmic Reticulum; Estra | 1976 |